SCHEMBL5916396

SCHEMBL5916396

Cc1nc(C)n2nc(-c3ccccn3)[nH]c(=O)c12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 3/20 0.59
PDE1A P54750 3/20 0.59
PDE1B Q01064 3/20 0.59
PDE1C Q14123 3/20 0.59
HTT P42858 5/20 0.47
ALDH1A1 P00352 5/20 0.47
L3MBTL1 Q9Y468 4/20 0.47
RAB9A P51151 4/20 0.47
LMNA P02545 3/20 0.47
NPC1 O15118 3/20 0.47
GAA P10253 1/20 0.47
HIF1A Q16665 1/20 0.47
SMN1; SMN2 Q16637 4/20 0.46
BTK Q06187 1/20 0.46
ATM Q13315 1/20 0.46
KDM4E B2RXH2 3/20 0.45
TDP1 Q9NUW8 2/20 0.45
POLB P06746 1/20 0.45
KRAS P01116 3/20 0.43
HSP90AA1 P07900 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1513983 0.81 PDE5A (0.60) PDE5APDE1APDE1BPDE1CALDH1A1
SCHEMBL8358527 0.77 PDE5A (0.53) PDE5APDE1APDE1BPDE1CALDH1A1
SCHEMBL12824019 0.76 PDE5A (0.65) PDE5APDE1APDE1BPDE1CALDH1A1
SCHEMBL8358658 0.75 PDE5A (0.52) PDE5APDE1APDE1BPDE1CALDH1A1
SCHEMBL13533558 0.74 PDE5A (0.77) PDE5APDE1APDE1BPDE1CHTT
SCHEMBL972561 0.74 PDE5A (1.00) PDE5APDE1APDE1BPDE1CALDH1A1
SCHEMBL8358661 0.74 PDE5A (0.53) PDE5APDE1APDE1BPDE1CRAB9A
SCHEMBL5916404 0.74 PDE5A (0.53) PDE5APDE1APDE1BPDE1CALDH1A1
SCHEMBL5233623 0.73 HTT (0.50) PDE5AHTTALDH1A1L3MBTL1RAB9A
SCHEMBL5619914 0.73 PDE5A (0.52) PDE5APDE1APDE1BPDE1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060166992-A1 Heterocyclically substituted imidazotriazines BAYER HEALTHCARE A G (DE) 2006-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060166992-A1 Heterocyclically substituted imidazotriazines SNCA, PARK7, TPMT PDE5A 2360/4885PDE1A 2215/4885PDE1B 2617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.